Making Better Choices in Diabetes Care With Multi-criteria Decision Making (MCDM)

By Charmi Patel

June 10, 2024

Introduction

Diabetes mellitus, a chronic condition affecting millions globally, demands nuanced decision-making across various aspects of patient care. Effective management hinges on informed choices regarding medication, diet, lifestyle, and treatment options. Multicriteria Decision-Making (MCDM) techniques offer a systematic approach to navigate the complexities of diabetes care.

By analysing 63 articles from 2003 to 2023 using the PRISMA method, distinct categories emerged, including medication selection, diagnosis, meal recommendations, management, complications, and prevalence estimation. Notably, the Analytic Hierarchy Process (AHP) emerged as a prominent tool across these categories, offering structured decision-making support. The findings underscore the versatility and potential impact of MCDM techniques in optimising diabetes care.

Figure 1
Figure 1: Multi-criteria decision-making (MCDM)

Medication Selection

Among the key areas where MCDM techniques shine is in medication selection. Studies reveal that MCDM methods, particularly AHP, play a pivotal role in aiding clinicians in choosing optimal diabetes medications. By weighing factors like efficacy, safety, and cost, these techniques facilitate evidence-based decisions tailored to individual patient needs.

MCDM techniques overview
Figure 3: MCDM techniques overview

Diagnosis and Meal Recommendations

MCDM techniques extend beyond medication selection, encompassing diagnosis and meal planning. From predicting diabetes risks to recommending dietary choices, these methods provide structured frameworks for healthcare providers to navigate the complexities of diabetes care. Notably, AHP emerges as a versatile tool in guiding diagnostic decisions and meal recommendations for patients with diabetes.

Diabetes Management and Complications

Effective diabetes management requires a comprehensive approach that considers various factors such as social support, treatment compliance, and risk assessment for complications. MCDM techniques, including ANP and TOPSIS, aid in assessing current mHealth applications, prioritising resources, and evaluating the severity of diabetes-related complications. These methods offer a holistic view of diabetes care, enhancing decision-making processes for healthcare providers.

Future Research

The integration of MCDM techniques in diabetes management proves instrumental in optimising patient care and treatment outcomes. By offering structured decision-making frameworks, these methods empower healthcare providers to make informed choices across various aspects of diabetes care. As the prevalence of diabetes continues to rise, leveraging MCDM techniques can significantly enhance the quality of care provided to individuals with diabetes, ultimately improving health outcomes and quality of life.

Future research should explore integrating MCDM techniques with AI and machine learning to enhance decision-making in diabetes care. Tailoring MCDM methods to individual patient needs can promote personalised medicine. Expanding MCDM applications to areas like mental health assessment and long-term disease management is recommended. Involving a broader range of stakeholders will ensure user-friendly tools that meet diverse needs. Optimising resource allocation using MCDM methods can improve healthcare efficiency and access. Clinical trials and real-world evidence are needed to validate MCDM effectiveness.

Reference url

Recent Posts

HIV Prevention Partnerships: Expanding Access to Lenacapavir for Global Impact

By João L. Carapinha

April 17, 2026

HIV Prevention Partnerships between PEPFAR, The Global Fund, and Gilead Sciences are accelerating access to twice-yearly injectable lenacapavir for HIV pre-exposure prophylaxis (PrEP) in high-burden countries. Unprecedented Speed to Sub-Saharan Africa This additional i...
Escalating Public Spending: Semaglutide Off-Label Use Sparks €250 Million Fraud Investigation in ...
Semaglutide off-label use for weight loss is at the centre of a suspected €250 million fraud uncovered by Portugal’s Judicial Police within the National Health Service (SNS). According to the investigation reported on 15 April 2026, roughly half of all public spending on Ozempic (semaglutide) bet...
Advancing Inclusive Healthcare Strategies Through Social Impact and Sustainability

By João L. Carapinha

April 15, 2026

In this update we examine how Novartis is embedding inclusive healthcare strategies into its core business by launching ambitious long-term Social Impact and Sustainability (SI&S) targets that reach to 2040. These targets integrate innovation, access to medicines, global health, environmental...